β-hydroxybutyrate, pyruvate and metabolic profiles in patients with schizophrenia: A case control study
详细信息 查看全文
- 作者：Yu-Chi Huanga ; Pao-Yen Lina ; b ; Yu Leea ; Chih-Ching Wuc ; d ; Su-Ting Hsue ; Chi-Fa Hunga ; Chien-Chih Chena ; Mian-Yoon Chonga ; Chieh-Hsin Lina ; Liang-Jen Wangf ; g ; wangliangjen@gmail.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：β-HB ; β-hydroxybutyrate ; BMI ; body mass index ; FENN ; first-episode neuroleptic-naï ; ve ; HDL-C ; high-density lipoprotein-cholesterol ; LDL-C ; low-density lipoprotein-cholesterol ; MINI ; Mini International Neuropsychiatric Interview ; PANSS ; Positive and Negative Syndrome Scale ; WHO ; World Health Organization
- 刊名：Psychoneuroendocrinology
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：73
- 期：Complete
- 页码：1-8
- 全文大小：586 K
文摘
- •
This study investigates the potential roles of β-HB and pyruvate in patients with schizophrenia.
- •
Schizophrenic patients had significantly higher serum levels of β-HB than healthy control subjects.
- •
Pyruvate was higher in patients treated with olanzapine or clozapine than in those treated with other antipsychotics.
- •
Serum levels of β-HB may act as a potential indicator of energy utilization impairment for schizophrenia.